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Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) is intrinsically cross-resistant to virtually all b-lactam antibiotics. The
central determinant for the MRSA phenotype is the mecA gene, whose transcriptional control may be mediated by a
repressor (mecI) and a sensor/inducer (mecR1). The mecI-mecR1-mediated induction of mecA takes several hours rendering
the strains phenotypically susceptible in spite of the presence of the resistance gene. Therefore, it has been proposed that
the full resistance to b-lactams observed in many contemporary clinical MRSA strains requires a non-functional mecI-mecR1
regulatory system. The mecA gene is embedded in a large chromosomal cassette (the SCCmec element) for which several
structural types have been described. Some epidemic MRSA clones, typically expressing full b-lactam resistance, carry
SCCmec elements that contain an intact mecI-mecR1 locus (e.g. SCCmec types II and III). We have addressed this apparent
contradiction by first sequencing the mecI coding region and mecA promoter sequences in a collection of prototype MRSA
strains characterized by different SCCmec types. A conserved non-sense mutation within mecI was detected in all SCCmec
type III strains tested, presumably responsible for a non-functional truncated MecI protein and, therefore, explaining the full
resistance phenotype. In SCCmec type II strains no conserved mutations were found. We next transformed a collection of
prototype MRSA epidemic strains with a recombinant plasmid overexpressing a wild-type copy of mecI. Surprisingly, for the
great majority of the strains no significant alterations in the phenotypic expression of b-lactam resistance could be detected.
These findings were confirmed and further explored, challenging the currently accepted mechanism of mecA transcriptional
control. Our observations suggest the existence of yet unidentified additional determinants involved in the transcriptional
control of mecA gene and point to a revision of the mecA regulatory mechanism in contemporary MRSA strains.
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Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) is a leading
cause of nosocomial infections worldwide and has also emerged as
a community-associated pathogen [1]. MRSA are inherently
cross-resistant to virtually all b-lactam antibiotics, the most
effective and widely used class of antimicrobials. Moreover,
MRSA clinical strains are quite often multi-drug resistant,
reducing significantly the therapeutic options for the treatment
of staphylococcal infections.
The MRSA characteristic phenotype is due to the presence of
mecA, which encodes a penicillin-binding protein (PBP), PBP2a,
with reduced affinity for b-lactams [2,3]. mecA is embedded in a
large heterologous chromosomal cassette, the SCCmec element [4].
Some MRSA strains carry upstream to the mecA gene the
regulatory genes mecI-mecR1 encoding for a repressor and a
sensor/inducer of the mecA expression, respectively [5]. This
genetic organization is similar to the b-lactamase locus that
encodes for penicillin-resistance only, and contains the structural
gene (blaZ), a repressor (blaI) and a sensor/inducer (blaR1). Apart
from the identical structural organization between mec and bla
systems, there is also good homology between the inducers (61%
identity at the amino acid level) and the b-lactam binding domain
of the repressors (44% identity at the amino acid level). In fact,
there is a cross-talk between both regulatory systems, as each one
alone is able to control the transcription of mecA and blaZ [6,7].
However, the two regulatory systems differ remarkably in the
induction efficiency: the blaI-blaR1 system induces mecA in a few
minutes, whereas the mecI-mecR1 system takes several hours
[6,7,8]. Actually, the mecI-mecR1 mediated induction of mecA
expression is so slow that, in clinical terms, fully functional mecI
and mecR1 genes render the cell phenotypically susceptible in spite
of the presence of mecA – the so-called ‘‘pre-MRSA’’ phenotype
[5,9]. In agreement with this observation, the in vitro deletion of the
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lactams in staphylococci [5,9,10].
Based on those observations, it has been postulated that full
resistance to b-lactams, characteristic of many contemporary
MRSA clinical strains, implies a non-functional mecI-mecR1
regulatory system [5,9]. As a matter of fact, the absence of mecI
or the accumulation of point mutations in the mecI coding
sequence, mecI ribosomal binding site or mecA gene promoter, have
been found in several MRSA strains [11,12,13,14,15]. Neverthe-
less, in spite of the negative effect of the presence of MecI on the
phenotypic expression of resistance, there is no clear direct
correlation between the cellular amounts of mecA transcript or
PBP2a protein and the phenotypic level of resistance (i.e. the
minimum inhibitory concentration, MIC, for the strain) [16,17].
Finally, the existence of other unknown determinants involved in
mecA regulation, for instance mediating the signal transduction
between the activated MecR1 and the promoter bound MecI, has
been postulated based on contradictory experimental observations
[13,15,18] and critical structural data analysis [19,20]. Early
studies on the b-lactamase regulon in S. aureus by Cohen and
Sweeney have also suggested the existence of the blaR2 locus,
unlinked to blaI-blaR1 and able to mediate the constitutive
expression of blaZ [21].
Currently, MRSA clones are defined not only based on the type
of genetic lineage but also on the type of SCCmec element they
carry, as the same lineage may be associated with several SCCmec
types [22,23]. Several structural types of the SCCmec element have
been described differing in size and genetic content [24]. The
genetic organization of the mecA vicinity (mec gene complex) is one
of the key characteristics used to define SCCmec types. In S. aureus
three major mec classes have been described based mainly on the
presence of insertion sequences and intact or disrupted mecI-mecR1
sequences: class A has intact sequences for mecI-mecR1, whereas
classes B and C have no mecI and partially deleted mecR1 due to the
integration of insertion sequences in the regulatory region of the
mecA. Considering the eight major SCCmec types described so far
in S. aureus, the mec gene complex class A characterizes SCCmec
types II, III and VIII; class B, SCCmec types I, IV and VI; and
class C, SCCmec types V and VII. According to the current model
of mecA transcriptional control [5,9], it is tempting to interpret the
disruption of the mecI-mecR1 regulatory system in SCCmec types I
and IV–VII, as a strategy to overcome the tight mecA repression
mediated by mecI-mecR1 system in MRSA strains. However, it
seems that there is no clear correlation between resistance levels
and mecI-mecR1 functionality, as some strains lacking mecI-mecR1
have a very low resistance level, whereas some strains with
complete mecI-mecR1 locus are highly resistant [14,15,25]. In
addition, the epidemicity of MRSA strains does not correlate with
the mecI-mecR1 functionality as well. For example, two major
pandemic nosocomial MRSA clones – the New York/Japan (or
ST5-II) and the Brazilian (or ST239-III) clones – are characterized
by SCCmec types II and III, respectively, and have a complete
mecI-mecR1 locus [22,23].
In this study, we have addressed the puzzling lack of correlation
between SCCmec type (i.e. mec gene class) and resistance phenotype
in order to clarify how the mecA transcription is controlled in
pandemic MRSA strains. We first characterized by DNA
sequencing the mecA regulatory locus in prototype strains of
SCCmec types II and III (i.e. with a complete mecI-mecR1 locus). We
found a conserved point mutation within the mecI coding-sequence
among SCCmec type III strains, which introduces a premature stop
codon resulting in truncated MecI repressor. Among the SCCmec
type II strains we could not find any conserved sequence alteration
either in the mecI coding sequence or in the mecA promoter that
could suggest a non-functional mecI-mecR1 system and, as such,
justify the high-resistance levels to b-lactams. We thus decided to
challenge the current model of mecA regulation by over-expressing
in trans the wild-type MecI in a collection of prototype MRSA
clinical strains. To our surprise, in most strains we could not detect
any significant alterations in the phenotypic expression of oxacillin
resistance. These observations suggest that other yet uncharacter-
ized factors are involved in the control of the expression of b-
lactam resistance in MRSA, namely by interfering with the mecI-
mediated repression of mecA, and point to a revision of the current
model for the transcriptional control of the resistance determinant
in contemporary strains.
Materials and Methods
Bacterial strains and culture conditions
MRSA strains used in this study and their relevant character-
istics are listed in Tables 1 and 2. All strains have been selected
from large international collections and have been previously
characterized in detail for genetic background by pulsed-field gel
electrophoresis (PFGE), multi-locus sequence typing (MLST), and
spa typing and also for SCCmec type. In Table 1, we have included
prototype strains for three major pandemic MRSA lineages
characterized by SCCmec types I–III [22]: the Iberian or ST247-I
clone, the New York/Japan or ST5-II clone, and the Brazilian or
ST239-III clone. In addition, in Table 1 we have also included two
reference strains extensively used in studies addressing the b-
lactam resistance mechanisms in S. aureus: strains COL [26] and
N315 [9]. Strain COL is highly and homogenously resistant to
oxacillin, has a non-functional mecI-mecR1 system, it naturally lacks
b-lactamase, and constitutively expresses mecA [26,27]. Strain
N315, has a very heterogeneous oxacillin-resistance phenotypic
profile, has wild-type mecI-mecR1 sequences, is b-lactamase positive
and has an inducible expression of mecA [5,9]. In Table 2, we list
further MRSA strains that were selected to extended our initial
collection in order to confirm the experimental observations. For
this purpose, we have included more representative SCCmec type
II strains and also strains characterized by SCCmec types IV–VI
[28,29,30]. S. aureus strains were routinely grown overnight at
37uC under aerobic conditions on tryptic soy agar or tryptic soy
broth (Difco, BD). Escherichia coli strains were grown in Luria-
Bertani broth (Difco, BD) with aeration at 37uC. Chloramphenicol
(20 mg/ml) and ampicillin (100 mg/ml) (Sigma-Aldrich) were used
for selection and maintenance of S. aureus and E. coli transformants,
respectively.
DNA manipulations
DNA manipulations were performed by standard methods
[31,32]. Restriction enzymes were used as recommended by the
manufacturer (New England Biolabs). Routine PCR amplification
was performed with AmpliTaq DNA polymerase (Applied
Biosystems) according to the manufacturer’s recommendations.
Wizard Plus Minipreps and Midipreps (Promega) purification
systems were used for plasmid extraction. PCR and digestion
products were purified with Wizard PCR Preps and Wizard DNA
Clean-up systems (Promega). Ligation reactions were performed
with the Rapid DNA Ligation Kit (Roche). DNA sequencing was
performed by the Rockefeller University Protein/DNA Technol-
ogy Center or by Macrogen (www.macrogen.com).
b-lactamase detection
Detection of functional b-lactamase locus was performed either
with BBL
TM DrySlide
TM Nitrocefin (BD) (strains listed in Table 1)
or with nitrocefin disks (Sigma-Aldrich) (strains listed in Table 2)
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Relevant characteristics Oxacillin MIC (mg/ml)
e)
Strain Origin
Isolation
date
Clonal
a)
type mecI
b) mecR1
c) PmecA bla
d)
Parental
strain
Recombinant
strain
f)
COL UK 1965 ST250 – I neg. IS::DmecR1 WT neg. .256 1.5
PER34 Spain 1989 ST247 – I neg. IS::DmecR1 WT pos. .256 .256
HPV107 Portugal 1992 ST247 – I neg. IS::DmecR1 WT pos. .256 .256
N315 Japan 1982 ST5 – II WT WT WT pos. 32 24
BK2464 USA 1996 ST5 – II WT WT WT pos. .256 .256
HU25 Brazil 1993 ST239 – III mecI
* WT WT pos. .256 .256
BK2421 USA 1996 ST239 – III mecI
* DmecR1 WT pos. .256 .256
Abbreviations: neg., negative; pos., positive; WT, wild-type.
Notes:
a)Clonal types as defined by MLST sequence type (ST) and SCCmec type.
b)neg. – negative (due to IS1272 insertion); WT – wild-type sequence (N315);
*- mutated non-functional mecI at Gln68 (CAARTAA);
c)IS::DmecR1 – mecR1 with no C-terminal sensor domain (due to IS1272 insertion); DmecR1 – 160 bp deletion in the C-terminal inducer domain.
d)The production of b-lactamase was assayed in induced and no induced cultures (see text for details). All strains positive for b-lactamase were inducible.
e)MIC as determined by E-test strips.
f)Parental strains transformed with a high copy number plasmid containing the wild-type mecI coding region (pGC2-mecI
WT).
doi:10.1371/journal.pone.0023287.t001
Table 2. Characteristics of the extended collection of representative MRSA strains.
Strain Origin
Isolation
date
Clonal
a)
type Relevant characteristics Oxacillin MIC (mg/ml)
e)
mecI
b) mecR1
c) PmecA b-lact.
d) Parental strain
Recombinant
strain
f)
USA100 USA 1995–2003 ST5-II pos. pos. ND pos. 64 64
USA200 USA 1995–2003 ST36-II pos. pos. ND pos. .256 .256
HAR24 Finland 2002 ST36-II pos. pos. ND pos. .256 .256
USA600 USA 1995–2003 ST45-II pos. pos. ND pos. .256 .256
MW2 USA 1998 ST1-IV neg. IS::DmecR1 ND pos. 32 32
HAR22 Finland 2002 ST22-IV neg. IS::DmecR1 ND pos. .256 .256
USA400 USA 1995–2003 ST1-IV neg. IS::DmecR1 ND pos. 96 96
USA800 USA 1995–2003 ST5-IV neg. IS::DmecR1 ND pos. 48 32
VNG17 Portugal 1992–1993 ST5-IV neg. IS::DmecR1 WT neg. 16 0.25
RJP17 Portugal 1992–1993 ST5-IV neg. IS::DmecR1 WT neg. 32 24
HSA49 Portugal 1993 ST5-IV neg. IS::DmecR1 ND pos. 24 24
USA300 USA 1995–2003 ST8-IV neg. IS::DmecR1 ND pos. 24 16
USA500 USA 1995–2003 ST8-IV neg. IS::DmecR1 ND pos. .256 .256
HAR38 Belgium 1995 ST45-IV neg. IS::DmecR1 ND pos. 128 128
USA700 USA 1995–2003 ST72-IV neg. IS::DmecR1 ND pos. 48 48
DEN2949 Denmark 2001 ST80-IV neg. IS::DmecR1 ND pos. 64 64
WIS Australia 1995 ST45-V neg. IS::DmecR1 ND pos. 4 4
HDE288 Portugal 1996 ST5-VI neg. IS::DmecR1 ND pos. 6 6
Abbreviations: neg., negative; pos., positive; WT, wild-type; ND, not determined.
Notes:
a)Clonal types as defined by MLST sequence type (ST) and SCCmec type.
b)neg. – negative (due to IS1272 or IS431 insertions); WT – wild-type sequence (N315); * - mutated non-functional mecI.
c)IS::DmecR1 – mecR1 with no C-terminal sensor domain (due to IS1272 or IS431 insertions).
d)The production of b-lactamase was tested for induced and no induced cultures (see text for details). All strains positive for b-lactamase were inducible. Strains negative
for the nitrocefin assay were tested for the presence of blaZ, blaI, and blaR1 by PCR.
e)MIC as determined by E-test strips.
f)Parental strains transformed with a high copy number plasmid containing the wild-type mecI coding region (pGC2-mecI
WT).
doi:10.1371/journal.pone.0023287.t002
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grown overnight in TSB with and without induction with oxacillin
at 0.5 mg/ml. Results were recorded after 30 min. incubation at
room temperature. In the case of strains negative for the Nitrocefin
assay, the absence of b-lactamase genes was confirmed by PCR
with three pairs of primers targeting internal fragments of ca.
500 bp of blaZ, blaI, and blaR1. Primers were designed based on
the available sequence at GenBank for Tn552 of S. aureus
(accession number: X52734); primer sequences were as follows
(59R39): blaZ F, GAT AAG AGA TTT GCC TAT GC; blaZ R,
GCA TAT GTT ATT GCT TGA CC; blaI F, GCA AGT TGA
AAT ATC TAT GG; blaI R, GAA AGG ATC CAT TTT CTG
TAC ACT CTC ATC; blaR1 F, CAT GAC AAT GAA GTA
GAA GC; and blaR1 R, CTT ATG ATT CCA TGA CAT ACG.
Phenotypic analysis
Initial susceptibility screening to oxacillin was determined for
all parental and recombinant strains with 1 mg oxacillin diffusion
disks prepared in-house [33]. For the MIC determination
oxacillin E-test strips (AB Biodisk) were used for all strains.
Overnight TSB cultures were adjusted to an optical density at
620 nm (OD620) of 0.08 (equivalent to 0.5 McFarland), plated
onto Muller Hinton agar (Difco) plates supplemented with 2%
NaCl, and incubated at 37uC for 24 h. Strains listed in Table 1
were also tested by population analysis profiles (PAPs), as
previously described [34,35]. In short, 10 ml drops of 10
0,1 0
21,
10
22,1 0
23,1 0
24,1 0
25,a n d1 0
26 dilutions of an overnight
culture were plated on TSA plates containing 0, 0.75, 1.5, 3, 6,
12.5, 25, 50, 100, 200, 400, 800 mg/ml of oxacillin (Sigma). For
each oxacillin concentration, colonies were counted for the first
dilution with non-confluent growh after 24 h and 48 h of
incubation at 37uC.
DNA sequencing of mecI and the mecA promoter
Based on the sequence of the mecA regulatory region for the
reference strain N315 (accession number D86934) two primer sets
were designed for the amplification and sequencing of the mecI
coding region and the promoter region of the mecA gene (PmecA).
Primer sequences were as follows (59R39): mecI F, TTA CGC
TTA CCG CTT TTTCG; mecI R, ATC AAG ACT TGC ATT
CAG GC; PmecA F, GTA ACA GAT GAT TGT TGA CC;
PmecA R, AAG ATG AAG TGG TAA TAG CG. DNA
sequencing raw data analysis and multi-sequence alignments were
performed using the DNA Star software package (Lasergene). All
sequences have been deposited in GenBank with accession
numbers JF946491–JF946513.
Recombinant strains
A DNA fragment containing the wild-type mecI coding region
and the putative ribosomal binding site from the prototype strain
N315 was amplified by PCR with the high-fidelity Pfu Turbo DNA
polymerase (Stratagene, La Jolla, CA) with primers 59-ATG GGA
ATT CAG CAC AAC AAA TTT CTG AGC-39 (forward) and
59-AGA GGG GAT CCT CAA CGA CTT GAT TGT TTC C-
39 (reverse) containing the underlined recognition sequences for
endonucleases EcoRI and BamHI, respectively. Using the same
strategy a PCR fragment containing a non-functional mecI coding
sequence (mecI*) was obtained from strain ANS46, a prototype
strain for SCCmec type III strain with a non-sense mutation at
Gln68 in the mecI coding sequence [22,36]. (CAARTAA) . A DNA
fragment containing the wild-type mecI-mecR1 coding regions and
the putative ribosomal binding sites from the prototype strain
N315 was also amplified by PCR with Pfu Turbo DNA
polymerase with forward primer 59-GTT CGA ATT CTT CTA
CTT CAC CAT TAT CGC-39 (containing the underlined
recognition sequences for endonuclease EcoRI) and the same
reverse primer described above. After double digestion and
purification, the inserts were directionally cloned into the multiple
cloning site of pGC2. pGC2 is a high-copy number E. coli-S. aureus
shuttle plasmid with resistance determinants to ampicillin (E. coli)
and chloramphenicol (S. aureus), obtained from P. Matthews, in
which the multiple cloning site is flanked by the strong SP6 and T7
bacteriophage promoters. After ligation the recombinant plasmids
were transformed and propagated in E. coli strain DH5a. The
integrity of the mecI
WT, mecI*, and mecImecR1 insert sequences was
verified by DNA restriction analysis and sequencing. The
recombinant plasmids were then introduced into the restriction-
deficient S. aureus strain RN4220 (R. Novick) by electroporation
with a Gene Pulser apparatus (Bio-Rad, Hercules, Calif.)
essentially as previously described [37] and then transduced into
the MRSA clinical strains by using phage 80a, as previously
described [38].
For the electrophoretic mobility shift assay, the wild-type coding
sequences of MecI and BlaI were fused to a histidine tag at the N-
terminal. Inserts were obtained by PCR with the Pfu Turbo DNA
polymerase using DNA from the prototype strain N315 as
template and the following primers (59R39): mecI Q1, TCA
GGG ATC CGA TAA TAA AAC GTA TGA AAT ATC ATC
TGC (forward); mecI Q2, GAG GAA GCT TTC AAC GAC
TTG ATT GTT TCC (reverse); blaI Q1, GTC TGG ATC CGC
CAA TAA GCA AGT TGA ATA TCT ATG G-3 (forward); and
blaI Q2, GAC AAA GCT TAT TTT CTG TAC ACT CTC
ATC (reverse), containing the underlined recognition sequences
for endonucleases BamHI (forward) and HindIII (reverse). After
double digestion and purification, the inserts were directionally
cloned into the multiple cloning site of pQE-30 (Qiagen), an E. coli
expression vector containing the coding sequence for a tag of
histidines upstream the BamH1 restriction site. After ligation the
recombinant plasmids were transformed and propagated in E. coli
strain M15 (Qiagen). The integrity of insert sequences was verified
by DNA restriction analysis and sequencing.
Total RNA isolation and Northern blot analysis
Overnight cultures were grown in TSB, supplemented with
chloramphenicol (10 mg/ml) when appropriate, and then diluted
1:50 in fresh TSB. After cells were grown to the mid-log phase
(OD620,0.7), they were pelleted and processed with the
FastRNA Blue isolation kit (Bio101, QBiogen) in combination
with FastPrep FP120 (Bio101-Savant, QBiogen), according to
the manufacturer’s recommendations. For the analysis of the
mecA induction profile, after cultures were grown to OD620,0.7,
oxacillin at 0.5 mg/ml was added and cultures were incubated
for an additional 60 minutes. Samples were taken at 0, 5, 15, 30,
and 60 minutes, pelleted and kept on ice until being simulta-
neously processed with the FastRNA Blue isolation kit. Total
RNA (5 mg) was resolved through a 1.2% agarose-0.66 M
formaldehyde gel in MOPS (morpholine propanesulfonic acid)
running buffer (Sigma). Blotting of RNA onto Hybond N+
membranes (Amersham) was performed with Turboblotter
alkaline transfer systems (Schleicher & Schuell). For detection
of mecA specific transcripts, a DNA probe was constructed by
PCR amplification with primers (59R39): mecA P1, AAA TCG
ATG TAA AGG TTG GC and mecA P2, GTT CTG CAG TAC
CGG ATT TG. After purification the probe was labeled with a
Ready To Go labeling kit (Amersham) by using [a-
32P]dCTP
(Amersham) and was hybridized under high-stringency condi-
tions. The blots were subsequently washed and autoradio-
graphed.
Overexpression of mecA Repressor in MRSA
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Expression and purification of MecI and BlaI N-terminal
histidine tag fusions (His-MecI and His-BlaI, respectively) was
performed in native conditions for 200 ml induced cultures using a
Ni-NTA matrix (Qiagen), as recommended by the manufacturer.
The purification procedure and recombinant protein purity was
evaluated by SDS-PAGE analysis. The concentrations of purified
His-MecI and His-BlaI proteins were estimated using the BCA
Protein Assay Kit (Pierce), as recommended by the manufacturer.
For the electrophoretic mobility shift assay we used the
chemiluminescent-based DIG Gel Shift Kit (Roche), following
the manufacturer’s recommendations. As DNA target we used a
c.a. 200 bp fragment encompassing the mecA promoter and
operator sequences from prototype strain COL obtained by
PCR amplification with primers (59R39): mecA PF1, ATA TCG
TGA GCA ATG AAC TG (forward) and mecA PR1, TAT ATA
CCA AAC CCG ACA AC (reverse).
Results
Characterization of the prototype MRSA strains
The resistance-level to oxacillin of the prototype MRSA strains
listed in Table 1 was checked with the oxacillin E-test. All strains
were classified as fully resistant to oxacillin: MIC$32 mg/ml. The
presence of inducible and functional expression of b-lactamase was
also checked through the hydrolysis of the chromogenic substrate
nitrocefin for overnight cultures grown in the presence or absence
of an inducer (oxacillin at sub-MIC concentration of 0.5 mg/ml).
All strains in Table 1, except the reference strain COL, were
positive for b-lactamase and its expression was found to be
inducible in the presence of oxacillin, suggesting a complete and
functional bla locus (blaI-blaR1-blaZ).
The mecI sequence was determined for a total of 11 previously
characterized strains positive for the mecI-mecR1 locus [22]: three
classified as ST5, SCCmec type II (including strains N315 and
BK2464 listed in Table 1) and eight classified as ST239, SCCmec
type III (including strains HU25 and BK2421 listed in Table 1). A
conserved point mutation was found in all SCCmec type III strains.
The mutation introduced a premature stop codon at Gln68
(CAARTAA) originating a truncated repressor protein (mecI*).
Among the SCCmec type II strains, a point mutation (GGAGRG-
GAA) in the mecI ribosomal binding site (RBS) was detected in one
strain (BK2464). No mutations were found within the mecI coding
region for the two other SCCmec type II strains. A total of 10
previously characterized strains [22], including all strains listed in
Table 1, were also sequenced for the mecA promoter region. Except
for one mutation in the position 25 detected in a ST5, SCCmec
type II strain, no point mutations were found in the promoter
sequence of the mecA gene, when compared to the published
sequence for the prototype strain N315 [5].
The induction profile of mecA transcription was checked by
northern blotting analysis upon exposure to oxacillin for three
prototype strains - PER34, HU25 and N315 - representing
different SCCmec types and, therefore, with functional and non-
functional mecI-mecR1 regulatory locus (Table 1 and Figure 1).
The three strains tested were shown to have an inducible mecA
expression independently of being positive or negative for a
functional copy of the mecI-mecR1 locus although there was a
remarkable difference in the induction efficiencies: strains PER34
and HU25 (mecI negative and truncated mecI, respectively) showed
a complete induction of mecA after 15 minutes, whereas for strain
N315 (wild-type sequence for mecI-mecR1) the induction was not
complete even after 60 minutes of induction. Since the three
strains were positive for the b-lactamase locus, these observations
confirm that mecA transcription can in fact be under the control of
the blaI-blaR1 regulatory locus in clinical MRSA strains and are
also in agreement with the previous reported differences of
induction efficiency of mecA between the mecI-mecR1 and the blaI-
blaR1 systems.
Overexpression of the mecA repressor in prototype MRSA
strains
From the above characterization of the prototype MRSA strains
listed in Table 1, we were able to justify the high-level oxacillin
resistance for strains carrying SCCmec types I and III. These were
found to have no functional mecI-mecR1 regulatory loci either due
to the characteristic presence of an insertion sequence (SCCmec
type I) or due to the conserved non-sense mutation within the
coding region of mecI (SCCmec type III) identified in this study.
However, for SCCmec type II strains we could not explain the
high-resistance phenotype since, except for the point mutation in
the mecI RBS of strain BK2464, no consistent alteration within the
mecI coding region or mecA promoter sequence was detected.
To explore these puzzling observations, we have overexpressed
in trans the mecA repressor in the prototype MRSA strains and
compared the phenotypic expression of b-lactam resistance
between the parental and transformed strains. For this purpose,
all strains listed in Table 1 were transformed with a high-copy
plasmid containing a wild-type copy of mecI of strain N315 (pGC2-
mecI). Strain COL transformed with pGC2-mecI showed a
dramatic decrease of the oxacillin resistance level according to
the PAP profile (see Figure 2, panel A) and the MIC as determined
by E-test dropped from .256 to 1.5 mg/ml. Strains N315 and
BK2464 (SCCmec type II) showed a slight decrease of the oxacillin
resistance level according to the PAP profiles (see Figure 2, panel
C for PAP profile of strain BK2464), although by E-test there was
no detectable decrease for strain BK2464 (MIC.256 mg/ml for
both parental and recombinant strains) and only a slight decrease
for strain N315 (from 32 to 16 mg/ml). Strains PER34 and
HPV107 (SCCmec type I) and HU25 and BK2421 (SCCmec type
III) showed no significant alteration of the oxacillin resistance
phenotypic expression profile (see Figure 2, panels B and D, for
PAP profiles of strains PER34 and HU25, respectively) nor in the
MIC as determined by the E-test (MIC.256 mg/ml for all cases).
A control experiment was done with the mutated mecI sequence
found in SCCmec type III strains (mecI*). The cloning strategy was
exactly the same used for obtaining the recombinant plasmid
pGC2-mecI. When strain COL was transformed with pGC2-mecI*
no significant alteration of the oxacillin resistance level was
detected – see Figure 2, Panel A. Moreover, the northern blot
Figure 1. Northern blot analysis of the mecA induction profile
in three prototype MRSA strains. Induction of mecA transcription
for three prototype strains upon exposure to oxacillin at 09,5 9,1 5 9,3 0 9,
and 609. Strain relevant characteristics are as follows: strain PER34 -
SCCmec type I, mecI negative, DmecR1; strain HU25 - SCCmec type III,
mecI*, mecR1
WT; strain N315 - SCCmec type II, mecI
WTmecR1
WT. The
three strains are b-lactamase positive.
doi:10.1371/journal.pone.0023287.g001
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COL and COL+pGC2-mecI*, whereas no mecA transcript could be
detected for COL+pGC2-mecI – see Figure 3, lanes 1–3.
Since strain COL is negative for the mecI and has a truncated
mecR1, the phenotype observed for COL+pGC2-mecI could be
explained by the lack of an inducer of the mecA transcription able to
release the mecI-mediated repression. To test this hypothesis, we have
transformed COL with a recombinant plasmid containing the wild-
type sequences for both mecImecR1 (pGC2-mecImecR1). Although by
northern blotting analysis the mecA transcription was restored after
overnight growth in the presence of oxacillin (see Figure 3, lanes 4–5),
suggesting a fully functional mecI-mecR1 regulatory system, no
significant increase on the oxacillin MIC was detected when
compared to COL+pGC2-mecI. Moreover, when grown in liquid
Figure 2. Population analysis profiles of representative parental strains and recombinant strains. Panel A – strain COL and its
recombinants strains COL+pGC2-mecI
WT, COL+pGC2-mecI*, and COL+pGC2-mecImecR1 grown overnight with and without oxacillin before plating
onto TSA plates. Panel B – strain PER34 (SCCmec type I) and PER34+pGC2-mecI
WT. Panel C – strain BK2464 (SCCmec type II) and BK2464+pGC2-mecI
WT.
Panel D – strain HU25 (SCCmec type III) and HU25+pGC2-mecI
WT.
doi:10.1371/journal.pone.0023287.g002
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cellular mass in solution (data not shown), suggesting a cellular toxic
effect due to the overexpression of MecR1.
Overexpression of mecI in an extended collection of
representative MRSA strains
In order to confirm the previous observations, all strains listed in
Table 2 were also transformed with the high-copy plasmid
containing the wild-type mecI (pGC2-mecI). This collection includes
four additional SCCmec type II strains, 13 SCCmec type IV strains,
and isolates for SCCmec types V and VI. SCCmec types IV–VI are
characterized by deletions in the mecImecR1 locus due to the
presence of insertion sequences. Once again, we could not detect
significant alterations in the phenotypic expression of oxacillin
resistance upon the overexpression of the mecA repressor, except
for one strain negative for the nitrocefin assay (VNG17). However,
for another nitrocefin negative strain (RJP17) the resistance
phenotype was stable. The absence of b-lactamase was confirmed
for these two strains by PCR amplification of internal fragments of
blaZ, blaI and blaR1. No amplification signals were detected. DNA
sequencing of the mecA promoter region for both strains revealed
no mutations in the operator sequences but a point mutation in the
mecA ribosomal-binding site was identified by comparison to the
wild-type sequence of strain N315 (GGA GGARGGA GTA).
Relative affinity of MecI and BlaI for the mecA promoter
sequence
In an attempt to explain the lack of effect on the resistance
phenotype upon the overexpression of mecI, we have evaluated the
in vitro relative binding affinity of MecI and BlaI repressors to the
mecA operator sequences by an electrophoretic mobility shift assay
(EMSA). For this purpose, we have expressed in E. coli N-terminal
histidine-tag fusions to the wild-type protein sequences of
prototype strain N315 (His-MecI and His-BlaI) and evaluated
the binding of purified proteins to a DNA fragment containing the
mecA promoter sequences of prototype strain COL. As illustrated
in Figure 4, by using equivalent concentrations of the purified
MecI and BlaI repressors, lower amounts of recombinant MecI
protein are required to induce an electrophoretic shift of the DNA
fragment containing the mecA promoter; i.e., suggesting that the
cognate repressor of mecA has an increased affinity for its promoter
sequences.
Discussion
The transcription of mecA, the gene responsible for the ‘‘broad-
spectrum’’ b-lactam resistance in S. aureus, may be controlled by
two regulatory systems: mecI-mecR1 and blaI-blaR1. Due to the
extremely slow induction of mecA expression mediated by mecI-
mecR1 regulators, it is believed that the high-level b-lactam
resistance characteristic of many contemporary clinical MRSA
strains requires a non-functional mecI-mecR1 regulatory locus [5,9].
In this study we aimed to understand how the mecA transcription
is regulated in contemporary pandemic MRSA strains, which in
many cases express full b-lactam resistance. Based on previous
studies by us and many others on the global epidemiology of
MRSA, which included the characterization of the SCCmec
element, we could, based on the current model of the mecA
regulation, justify the potential for the expression of high-level b-
lactam resistance in many MRSA clones; i.e. all those clones
characterized by SCCmec types I and IV–VII, which have no-
functional mecI-mecR1 genes due to the presence of insertion
sequences. However, for MRSA clones characterized by SCCmec
types II, III and VIII, which carry a complete mecI-mecR1 region,
we could not explain the high-level b-lactam resistance phenotype.
In addition, as illustrated among the MRSA strains selected for
this study, no clear relationship exists between SCCmec type (i.e.
mecI-mecR1 functionality) and the level of resistance. For instance,
low-level resistance is detected among SCCmec type IV strains that
have no functional mecI-mecR1 locus.
Upon DNA sequencing of the mecI coding region, we found a
conserved non-sense mutation at Gln68 in all SCCmec type III
strains tested. This mutation leads to a truncated MecI protein of
67 a.a. (instead of the 123 a.a. of the wild-type). This mutation
appears to be conserved in the ST239-III lineage since it has also
been detected in all isolates of a diverse international collection of
c.a. 60 ST239-III strains whose genomic sequences have been fully
Figure 3. Northern blotting analysis of mecA transcription in
COL transformants. Lane 1, parental strain COL; lane 2, COL+pGC2-
mecI
WT;l a n e3 ,C O L +pGC2-mecI*; lane 4, COL+pGC2-mecImecR1
uninduced; lane 5, COL+pGC2-mecImecR1 induced with oxacillin.
doi:10.1371/journal.pone.0023287.g003
Figure 4. Electrophoretic mobility shift assay of relative MecI
and BlaI affinities for the mecA promoter sequence. Binding
reaction was performed with a labeled 200 bp DNA fragment
encompassing the mecA promoter mixed with increasing amounts of
purified MecI (panel A) and BlaI (panel B). Lanes are as follows: lane 1 –
no protein (control); lane 2 – 0,001 mg; lane 3 – 0,01 mg; lane 4 –
0,05 mg; lane 5 – 0,1 mg; lane 6 – 0,25 mg; lane 7 – 0,5 mg; lane 8 – 1 mg;
lane 9 – 0,1 ug of protein with a 125 molar excess of unlabelled DNA
(specific competition).
doi:10.1371/journal.pone.0023287.g004
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detected in a cluster of 12 clinical MRSA strains and found to be
statistically associated to an increase in the mecA transcription,
suggesting a non-functional MecI protein [40]. In our northern
blotting experiments, overexpression of this mutated mecI failed to
repress the mecA transcription on the prototype strain COL that is
characterized by a constitutive expression of the resistance
determinant. Altogether, these observations suggest that this
conserved non-functional version of mecI accounts for the high-
level resistance phenotype of SCCmec type III strains.
Concerning SCCmec type II strains, we detected in strain
BK2464 a mutation within the ribosomal binding site (RBS) of
mecI, from GGAG to GGAA. This mutation has also been
previously detected among clinical MRSA strains and showed to
be statistically associated to a decrease of mecA repression [40],
which could explain high-levels of b-lactam resistance. However,
since we could not detect this mutation in the other two SCCmec
type II strains analyzed, neither in all genomic and SCCmec
sequences of type II strains available at GenBank (e.g. strains
MRSA252, Mu3, Mu50, JH1, JH9, etc.), it seems that this
alteration of the mecI RBS per se does not justify the b-lactam
resistance phenotype of SCCmec type II strains. Rosato et al have
also noticed that the mecI RBS differences could not entirely
explain the difference in mecA transcription between isolates [40].
Regarding the mecA promoter, we identified a point mutation
found in one single strain in the position 25, which theoretically
may affect the binding of MecI [41]. However, this mutation was
not detected either in the other SCCmec type II strains or in the
available genomic sequences and, as such, it also does not justify
the resistance phenotype of SCCmec type II strains. As we have not
sequenced mecR1, the hypothesis that the inducer is mutated and
able to induce mecA transcription more efficiently cannot be
excluded. Nevertheless, this hypothesis seems unlikely since no
mutations within the mecR1 coding sequence were detected among
genomic sequences available at Genbank, which include SCCmec
type II and fully oxacillin-resistant strains. In addition, in a large
study which addressed the allelic variation of mecA regulators only
two silent mutations were found within the mecR1 coding sequence
[25].
In order to further explore the puzzling observations described
above, we have cloned the wild-type sequence of mecI from the
reference strain N315 in a high-copy number plasmid with strong
bacteriophage promoters flanking the cloning site and we have
introduced this recombinant plasmid into prototype and repre-
sentative MRSA strains. By over-expressing the repressor in trans,
according to the current model for the mecA transcriptional
control, we were expecting to see a significant decrease in the
resistance level to oxacillin, particularly for strains naturally
negative for mecI (i.e. containing SCCmec types I and IV–VII). To
our surprise, except for strains COL and VNG17, the resistant
phenotype to oxacillin showed no significant changes in all strains.
Since we could see an effect in strains COL and VNG17, we were
confident about the functionality of the cloned mecI. Nevertheless,
we have also transformed COL with the truncated mecI found in
SCCmec type III strains cloned into the same plasmid using exactly
the same cloning strategy. As expected, the overexpression of the
truncated mecI failed to cause any phenotypic alterations. Northern
blotting analysis of mecA in COL and its transformants also showed
that only the wild-type mecI was able to repress the mecA
constitutive transcription of the parental strain. Because COL
has no functional mecR1, the phenotype observed could be
explained by the lack of an inducer able to release the mecI-
mediated repression on mecA, although this would also apply to all
other SCCmec types I and IV–VI tested for which there was no
effect upon the overexpression of mecI (except for strain VNG17).
Nevertheless, we have transformed COL with a recombinant
plasmid containing the full wild-type mecI-mecR1 system. Interest-
ingly, although we could see induction of mecA transcription in the
presence of oxacillin, the resistance phenotype of the parental
strain could not be restored. Moreover, the transformed strain
presented clear physiological perturbations when grown in liquid
medium, which suggests that the overexpression of MecR1, a
trans-membranar protein, might be toxic for the cell, as previously
observed [42].
The two strains for which the mecI overexpression caused a
decrease in the oxacillin-resistance level (COL and VNG17) were
negative for the b-lactamase locus, suggesting that this locus might
be responsible for the observed ‘‘resistance’’ of MRSA strains to
the mecI overexpression. Indeed, it has been shown that blaI-blaR1
can efficiently repress and induce mecA transcription [6,7]; we also
confirmed these observations by northern blotting analysis of the
mecA induction profile in three prototype strains (Figure 1).
However, two lines of evidence may reject this hypothesis. First, in
another b-lactamase negative strain (RJP17), belonging to the
same clone of VNG17 and isolated in the same country and time
period, we could not detect significant alterations in the oxacillin
resistance phenotype upon the overexpression of mecI. Second,
although blaI-blaR1 can efficiently induce mecA transcription, the
blaI-blaR1 and mecI-mecR1 systems are not inter-changeable; i.e.
BlaR1 is not able to release the MecI-mediated repression on mecA
[8]. That is to say, there is no evidence so far supporting the
hypothesis that the blaI-blaR1 system is able to out-compete the
MecI-mediated repression on mecA, which could eventually
account for the lack of effect on the resistance phenotype observed
in our overexpression experiments. Moreover, in our experimental
system the blaI-blaR1 expressed from its native promoter would
have to out-compete MecI expressed constitutively from a strong
bacteriophage promoter.
Inspired by the fact that the mecI-mecR1 and blaI-blaR1 systems
differ remarkably in the induction efficiency of mecA, we have
tested the hypothesis that our observations could be explained by
differences in the relative affinities of MecI and BlaI for the mecA
promoter sequences. We have addressed this hypothesis in vitro
through an electrophoretic mobility shift assay, which clearly
showed that lower concentrations of purified MecI are required for
detecting a binding to the DNA fragment containing the mecA
promoter sequences, suggesting an increased affinity when
compared to BlaI. Therefore, our observations could not be
explained by an increased affinity of BlaR1 for the mecA promoter,
which eventually would ‘‘protect’’ against the increased cellular
amounts of MecI. Actually, this hypothesis would make little sense
if one takes into account that the induction process involves the
proteolysis of BlaR1 and BlaI and that the sustained expression of
the resistance gene requires the continuous expression of both
regulatory proteins from their common promoter [43]. In our
experimental system, this signal transduction cascade would have
to out-compete the binding of MecI (overexpressed constitutively)
to the mecA promoter.
In short, this study has shown that unexpectedly the b-lactam
resistance phenotype of MRSA strains is not affected by the
overexpression in trans of the mecA repressor, even in strains
negative for or with non-functional mecI gene. This puzzling
observation, besides contradicting the current model for the mecA
transcriptional control in contemporary MRSA strains, strongly
suggests that other yet unidentified determinants are involved
directly or indirectly in the transcriptional control of the mecA gene
and, consequently in the phenotypic expression of b-lactam
resistance. Elucidation of the nature of these determinants is under
Overexpression of mecA Repressor in MRSA
PLoS ONE | www.plosone.org 8 August 2011 | Volume 6 | Issue 8 | e23287way and will be of paramount clinical relevance, since the full
understanding of the molecular mechanisms controlling the
phenotypic expression of the ‘‘broad-spectrum’’ b-lactam resis-
tance in clinical MRSA strains may contribute to the design of new
therapeutic strategies, which may extend the clinical utility of b-
lactams.
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